PortalPublikationenExpression of CCCTC-binding factor (CTCF) is linked to poor ...

Expression of CCCTC-binding factor (CTCF) is linked to poor prognosis in prostate cancer

Standard

Expression of CCCTC-binding factor (CTCF) is linked to poor prognosis in prostate cancer. / Höflmayer, Doris; Steinhoff, Amélie; Hube-Magg, Claudia; Kluth, Martina; Simon, Ronald; Burandt, Eike; Tsourlakis, Maria Christina; Minner, Sarah; Sauter, Guido; Büscheck, Franziska; Wilczak, Waldemar; Steurer, Stefan; Huland, Hartwig; Graefen, Markus; Haese, Alexander; Heinzer, Hans; Schlomm, Thorsten; Jacobsen, Frank; Hinsch, Andrea; Poos, Alexandra M; Oswald, Marcus; Rippe, Karsten; König, Rainer; Schroeder, Cornelia.

in: MOL ONCOL, Jahrgang 14, Nr. 1, 01.2020, S. 129-138.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Höflmayer, D, Steinhoff, A, Hube-Magg, C, Kluth, M, Simon, R, Burandt, E, Tsourlakis, MC, Minner, S, Sauter, G, Büscheck, F, Wilczak, W, Steurer, S, Huland, H, Graefen, M, Haese, A, Heinzer, H, Schlomm, T, Jacobsen, F, Hinsch, A, Poos, AM, Oswald, M, Rippe, K, König, R & Schroeder, C 2020, 'Expression of CCCTC-binding factor (CTCF) is linked to poor prognosis in prostate cancer', MOL ONCOL, Jg. 14, Nr. 1, S. 129-138. https://doi.org/10.1002/1878-0261.12597

APA

Höflmayer, D., Steinhoff, A., Hube-Magg, C., Kluth, M., Simon, R., Burandt, E., Tsourlakis, M. C., Minner, S., Sauter, G., Büscheck, F., Wilczak, W., Steurer, S., Huland, H., Graefen, M., Haese, A., Heinzer, H., Schlomm, T., Jacobsen, F., Hinsch, A., ... Schroeder, C. (2020). Expression of CCCTC-binding factor (CTCF) is linked to poor prognosis in prostate cancer. MOL ONCOL, 14(1), 129-138. https://doi.org/10.1002/1878-0261.12597

Vancouver

Höflmayer D, Steinhoff A, Hube-Magg C, Kluth M, Simon R, Burandt E et al. Expression of CCCTC-binding factor (CTCF) is linked to poor prognosis in prostate cancer. MOL ONCOL. 2020 Jan;14(1):129-138. https://doi.org/10.1002/1878-0261.12597

Bibtex

@article{00e349c802364b30bd75a6ec702f8b4a,
title = "Expression of CCCTC-binding factor (CTCF) is linked to poor prognosis in prostate cancer",
abstract = "The chromatin-organizing factor CCCTC-binding factor (CTCF) is involved in transcriptional regulation, DNA-loop formation, and telomere maintenance. To evaluate the clinical impact of CTCF in prostate cancer, we analyzed CTCF expression by immunohistochemistry on a tissue microarray containing 17 747 prostate cancers. Normal prostate tissue showed negative to low CTCF expression, while in prostate cancers, CTCF expression was seen in 7726 of our 12 555 (61.5%) tumors and was considered low in 44.6% and high in 17% of cancers. Particularly, high CTCF expression was significantly associated with the presence of the transmembrane protease, serine 2:ETS-related gene fusion: Only 10% of ERG-negative cancers, but 30% of ERG-positive cancers had high-level CTCF expression (P < 0.0001). CTCF expression was significantly associated with advanced pathological tumor stage, high Gleason grade (P < 0.0001 each), nodal metastasis (P = 0.0122), and early biochemical recurrence (P < 0.0001). Multivariable modeling revealed that the prognostic impact of CTCF was independent from established presurgical parameters such as clinical stage and Gleason grade of the biopsy. Comparison with key molecular alterations showed strong associations with the expression of the Ki-67 proliferation marker and presence of phosphatase and tensin homolog deletions (P < 0.0001 each). The results of our study identify CTCF expression as a candidate biomarker for prognosis assessment in prostate cancer.",
author = "Doris H{\"o}flmayer and Am{\'e}lie Steinhoff and Claudia Hube-Magg and Martina Kluth and Ronald Simon and Eike Burandt and Tsourlakis, {Maria Christina} and Sarah Minner and Guido Sauter and Franziska B{\"u}scheck and Waldemar Wilczak and Stefan Steurer and Hartwig Huland and Markus Graefen and Alexander Haese and Hans Heinzer and Thorsten Schlomm and Frank Jacobsen and Andrea Hinsch and Poos, {Alexandra M} and Marcus Oswald and Karsten Rippe and Rainer K{\"o}nig and Cornelia Schroeder",
note = "{\textcopyright} 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.",
year = "2020",
month = jan,
doi = "10.1002/1878-0261.12597",
language = "English",
volume = "14",
pages = "129--138",
journal = "MOL ONCOL",
issn = "1574-7891",
publisher = "Elsevier",
number = "1",

}

RIS

TY - JOUR

T1 - Expression of CCCTC-binding factor (CTCF) is linked to poor prognosis in prostate cancer

AU - Höflmayer, Doris

AU - Steinhoff, Amélie

AU - Hube-Magg, Claudia

AU - Kluth, Martina

AU - Simon, Ronald

AU - Burandt, Eike

AU - Tsourlakis, Maria Christina

AU - Minner, Sarah

AU - Sauter, Guido

AU - Büscheck, Franziska

AU - Wilczak, Waldemar

AU - Steurer, Stefan

AU - Huland, Hartwig

AU - Graefen, Markus

AU - Haese, Alexander

AU - Heinzer, Hans

AU - Schlomm, Thorsten

AU - Jacobsen, Frank

AU - Hinsch, Andrea

AU - Poos, Alexandra M

AU - Oswald, Marcus

AU - Rippe, Karsten

AU - König, Rainer

AU - Schroeder, Cornelia

N1 - © 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.

PY - 2020/1

Y1 - 2020/1

N2 - The chromatin-organizing factor CCCTC-binding factor (CTCF) is involved in transcriptional regulation, DNA-loop formation, and telomere maintenance. To evaluate the clinical impact of CTCF in prostate cancer, we analyzed CTCF expression by immunohistochemistry on a tissue microarray containing 17 747 prostate cancers. Normal prostate tissue showed negative to low CTCF expression, while in prostate cancers, CTCF expression was seen in 7726 of our 12 555 (61.5%) tumors and was considered low in 44.6% and high in 17% of cancers. Particularly, high CTCF expression was significantly associated with the presence of the transmembrane protease, serine 2:ETS-related gene fusion: Only 10% of ERG-negative cancers, but 30% of ERG-positive cancers had high-level CTCF expression (P < 0.0001). CTCF expression was significantly associated with advanced pathological tumor stage, high Gleason grade (P < 0.0001 each), nodal metastasis (P = 0.0122), and early biochemical recurrence (P < 0.0001). Multivariable modeling revealed that the prognostic impact of CTCF was independent from established presurgical parameters such as clinical stage and Gleason grade of the biopsy. Comparison with key molecular alterations showed strong associations with the expression of the Ki-67 proliferation marker and presence of phosphatase and tensin homolog deletions (P < 0.0001 each). The results of our study identify CTCF expression as a candidate biomarker for prognosis assessment in prostate cancer.

AB - The chromatin-organizing factor CCCTC-binding factor (CTCF) is involved in transcriptional regulation, DNA-loop formation, and telomere maintenance. To evaluate the clinical impact of CTCF in prostate cancer, we analyzed CTCF expression by immunohistochemistry on a tissue microarray containing 17 747 prostate cancers. Normal prostate tissue showed negative to low CTCF expression, while in prostate cancers, CTCF expression was seen in 7726 of our 12 555 (61.5%) tumors and was considered low in 44.6% and high in 17% of cancers. Particularly, high CTCF expression was significantly associated with the presence of the transmembrane protease, serine 2:ETS-related gene fusion: Only 10% of ERG-negative cancers, but 30% of ERG-positive cancers had high-level CTCF expression (P < 0.0001). CTCF expression was significantly associated with advanced pathological tumor stage, high Gleason grade (P < 0.0001 each), nodal metastasis (P = 0.0122), and early biochemical recurrence (P < 0.0001). Multivariable modeling revealed that the prognostic impact of CTCF was independent from established presurgical parameters such as clinical stage and Gleason grade of the biopsy. Comparison with key molecular alterations showed strong associations with the expression of the Ki-67 proliferation marker and presence of phosphatase and tensin homolog deletions (P < 0.0001 each). The results of our study identify CTCF expression as a candidate biomarker for prognosis assessment in prostate cancer.

U2 - 10.1002/1878-0261.12597

DO - 10.1002/1878-0261.12597

M3 - SCORING: Journal article

C2 - 31736271

VL - 14

SP - 129

EP - 138

JO - MOL ONCOL

JF - MOL ONCOL

SN - 1574-7891

IS - 1

ER -